Inflammatory Bowel Disease (IBD) Measures Group

**Measures**

- #110 Preventive Care and Screening: Influenza Immunization
- #111 Pneumonia Vaccination Status for Older Adults
- #226 Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
- #270 Inflammatory Bowel Disease (IBD): Preventive Care: Corticosteroid Sparing Therapy
- #271 Inflammatory Bowel Disease (IBD): Preventive Care: Corticosteroid Related Iatrogenic Injury – Bone Loss Assessment
- #274 Inflammatory Bowel Disease (IBD): Testing for Latent Tuberculosis (TB) Before Initiating Anti-TNF (Tumor Necrosis Factor) Therapy
- #275 Inflammatory Bowel Disease (IBD): Assessment of Hepatitis B Virus (HBV) Status before Initiating Anti-TNF (Tumor Necrosis Factor) Therapy

**Reporting Instructions**

(1) Identify patients with the following criteria:
- Aged 18 years and older on date of encounter
- Encounter during January 1 - December 31, 2016 with the following:
  One of the following diagnosis codes indicating IBD:
- and
- One of the following patient encounter codes:
  99201, 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215, 99341, 99342, 99343, 99344, 99345, 99347, 99348, 99349, 99350, 99406, 99407

* Recommended clinical performance satisfied
^ Patient is excluded from measure’s performance
Inflammatory Bowel Disease (IBD) Measures Group

(2) Report all applicable measures within the measures group for at least 20 patients.
   - The majority of the patients reported must be Medicare Part B Fee-for-service (FFS) patients, including Medicare Secondary and Railroad Medicare.
   - For each measure, the measure’s clinical performance must be satisfied for at least 1 patient. [Note: An asterisk (*) indicates that the measure’s clinical performance is satisfied.]

For additional information or clinical rationale for measures, review the CMS Measure Specification for 2016 PQRS. All measures group Measure Specifications can be found on the NYeC Provider Portal > Registry > Getting Started section.

* Recommended clinical performance satisfied
^ Patient is excluded from measure’s performance
**Patient Information**

First Name: [Input]
Middle Initial: [Input]
Last Name: [Input]
Date of Birth: [Input]
Visit Date: [Input]
Medical Record Number: [Input]
Gender: Male/Female
Medicare FFS Patient: Yes/No

**Select Measures Performance**

Select one (1) clinical action for each measure below, where applicable:

### #110: Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy – Avoidance of Inappropriate Use

*Patients who received an influenza immunization OR who reported previous receipt of an influenza immunization.*

- For **Visit Date 01/01/16-03/31/16**: Report if Received 08/01/15-03/31/16
- For **Visit Date 10/01/16-12/31/16**: Report if Received 08/01/16-12/31/16
  - Administered or previously received*
  - Not administered (Reason documented) ^
  - Not administered (No reason documented)

### #111 Pneumonia Vaccination Status for Older Adults

*Patients who have ever received a pneumococcal vaccination*

- Administered or previously received*
- Not administered or previously received

---

* Recommended clinical performance satisfied
^ Patient is excluded from measure's performance
#226 Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention

*Patients who were screened for tobacco use at least once within 24 months AND who received tobacco cessation counseling intervention if identified as a tobacco user*

- Identified as tobacco user and cessation intervention performed*
- Screened for tobacco use and identified as non-user of tobacco*
- Not screened for tobacco use (Medical reason documented) ^
- Identified as tobacco user and cessation intervention NOT performed
- Not screened for tobacco use (No reason documented)

#270 Inflammatory Bowel Disease (IBD): Preventive Care: Corticosteroid Sparing Therapy

*Prescribed a corticosteroid sparing therapy (e.g., thiopurines, methotrexate, or biologic agents)*

- Corticosteroid sparing therapy prescribed*
- No sparing therapy (Reason documented) ^
- No sparing therapy, no reason specified (No reason documented)

#271 Inflammatory Bowel Disease (IBD): Preventive Care: Corticosteroid Related Iatrogenic Injury – Bone Loss Assessment

*Patients who have received dose of corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600mg prednisone or greater for all fills and who were documented for risk of bone loss during the reporting year or the pervious calendar year.*

- Bone Loss assessment performed*
- Not receiving corticosteroid therapy^
- No Bone Loss assessment performed

* Recommended clinical performance satisfied
^ Patient is excluded from measure's performance
#274 Inflammatory Bowel Disease (IBD): Testing for Latent Tuberculosis (TB) Before Initiating Anti-TNF (Tumor Necrosis Factor) Therapy

Patients who had TB screening performed and results interpreted, within 6 months prior to receiving a first course of anti-TNF therapy

- TB screening test performed and results interpreted*
- Patient not receiving a first course of anti-TNF therapy*
- Screening not performed (Reason Documented)^
- Screening NOT performed (No Reason Documented)

#275 Inflammatory Bowel Disease (IBD): Assessment of Hepatitis B Virus (HBV) Status Before Initiating Anti-TNF (Tumor Necrosis Factor) Therapy

Patients who had HBV status assessed and results interpreted within one year prior to receiving a first course of anti-TNF therapy

- Hepatitis B Virus (HBV) status assessed and results interpreted within one year prior to receiving a first course of anti-TNF (tumor necrosis factor) therapy*
- Patient has documented immunity to hepatitis B and is receiving a first course of anti-TNF therapy*
- Hepatitis B Virus (HBV) status not assessed (Reason Documented)^
- Patient not receiving a first course of anti-TNF therapy^  
- Hepatitis B Virus (HBV) status not assessed (No Reason Documented)